Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18559184 | WDR5 INHIBITORS AND MODULATORS | Non-Final OA | Vanderbilt University |
| 19189953 | INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Final Rejection | MINDSET PHARMA INC. |
| 17886776 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | Final Rejection | REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18931783 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | Non-Final OA | Handa Oncology, LLC |
| 17721831 | OPHTHALMIC COMPOSITION | Non-Final OA | Sydnexis, Inc. |
| 17721838 | OPHTHALMIC COMPOSITION | Non-Final OA | Sydnexis, Inc. |
| 18740059 | DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF | Non-Final OA | Supernus Pharmaceuticals, Inc. |
| 18508831 | R-KETAMINE AND DERIVATIVE THEREOF AS PROPHYLACTIC OR THERAPEUTIC AGENT FOR NEURODEGENERATION DISEASE OR RECOGNITION FUNCTIONAL DISORDER | Final Rejection | National University Corporation Chiba University |
| 17781929 | METHOD OF TREATMENT WITH KCNQ CHANNEL OPENERS | Final Rejection | Icahn School of Medicine at Mount Sinai |
| 18416336 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | Final Rejection | Intervet Inc. |
| 18566862 | Administration of a Compound to Individuals with Hepatic Impairment | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18367424 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Non-Final OA | Eil Therapeutics, Inc. |
| 18222370 | COMPOUNDS HAVING ((3-NITROPHENYL)SULFONYL)ACETAMIDE AS BCL-2 INHIBITORS | Non-Final OA | Eil Therapeutics, Inc. |
| 17723828 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | Final Rejection | GNT Pharma Co., Ltd. |
| 17753065 | NOVEL OXADIAZOLE COMPOUNDS CONTAINING 5- MEMBERED HETEROAROMATIC RING FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | Non-Final OA | PI INDUSTRIES LTD. |
| 18078655 | METHOD OF TREATING CANCER HAVING AN ACTIVATED HEDGEHOG PATHWAY | Final Rejection | Endeavor Biomedicines, Inc. |
| 17770535 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | Final Rejection | MapLight Therapeutics, Inc. |
| 17640864 | Therapeutic Methods And Uses Thereof | Non-Final OA | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy